Compare AIV & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | SIGA |
|---|---|---|
| Founded | 1975 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.3M | 223.8M |
| IPO Year | 1996 | 2016 |
| Metric | AIV | SIGA |
|---|---|---|
| Price | $1.69 | $3.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 590.9K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 96.47% | 18.93% |
| EPS Growth | ★ 616.00 | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $138,486,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $170.70 |
| P/E Ratio | ★ N/A | $24.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.63 | $2.83 |
| 52 Week High | $6.04 | $8.54 |
| Indicator | AIV | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 13.76 | 45.93 |
| Support Level | N/A | $2.87 |
| Resistance Level | $4.30 | $3.32 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.22 | 18.75 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.